M&Aargenx buys macrocycle partner Unnatural Products for up to $1.15 billionDutch-Belgian immunology company argenx has agreed to acquire California-based Unnatural Products Inc. (UNP) for up to $1.15 billion (€1.03 billion), turning an existing drug-discovery partnership … more ➔
Deep DiveWhen genetic medicine enters the inner earGene therapies began as proof-of-concept treatments for a handful of rare genetic disorders and now, with emerging tools, may expand into broader territories with new targeted organs. This year, one … more ➔
clinical dataSpinal muscular atrophy: Tumors reported following Novartis gene therapyNine reports of tumors in children treated with Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma raise new questions about its long-term safety. In two cases, viral vector DNA was detected … more ➔
AppointmentsOculis taps Roche veteran after setback; ARTHEx brings in Azafaros’ CMO; CRISPR recruits Orna’s former CTOEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: neuroscience experience for Oculis, … more ➔
arthritisDutch biotech Anaheim launches with €40M to develop pseudogout treatmentDutch biotech Anaheim Bio, a spin-out of BioMarin-acquired Alesta Therapeutics, has launched with an oversubscribed €40 million Series A to advance ANA-1, a potential disease-modifying treatment for … more ➔
partneringBoehringer secures six Chinese cancer programs in deal worth up to $7BBoehringer is turning to China for cancer research in a multibillion-dollar deal with Sino Biopharmaceutical. Six preclinical programs involving antibody-drug conjugates (ADCs) and T-cell engagers are … more ➔
financeBioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliverThe Mainz-based vaccine developer is making progress in its transformation into an oncology company. But its quarterly report also shows how much work remains: Pumitamig is at the center of clinical … more ➔
Market accessBayer closes the gap with Boehringer in China’s lung cancer raceBayer brings sevabertinib into the first-line setting in China — but Boehringer is already there: With the approval of sevabertinib for the first-line treatment of HER2-mutated lung cancer, Bayer is … more ➔
fundraisingT-Therapeutics raises $133M to bring TCR bispecifics into clinicCambridge-based T-Therapeutics has raised $133 million (€118 million) in an oversubscribed Series B financing to advance two experimental T-cell engager therapies for cancer and autoimmune diseases … more ➔
startupOxford spinout Alethio raises $90M Series A for chronic blood cancer trialsUniversity of Oxford spinout Alethio Therapeutics has raised $90 million (about €80 million) to take its G6B-targeting antibody ATX-011 into clinical trials for essential thrombocythemia. The proceeds … more ➔
